PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced it has...

PAVmed Reports Second Quarter 2019 Financial Results and Provides Business Update Conference call to be held on September 5, 2019 at 4:30 p.m. Eastern time NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...

PAVmed Successfully Completes Clinical Safety Study Procedures for CarpX™ 510(k) Re-submission All 20 patients underwent successful CarpX procedures while passing primary effectiveness endpoint, with all follow-up patients to date passing primary safety endpoint NEW YORK, Aug. 15, 2019 ...

PAVmed Reports Excellent DisappEAR™ Animal Study Results Resorbable pediatric ear tube expected to benefit up to one million U.S. children per year NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or...

PAVmed to Hold Business Update Conference Call on April 4, 2019 NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...